The UK and US have agreed to a major commercial pact that will guarantee zero levies on British pharmaceutical products being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these crucial exports will be held at zero for a timeframe of three years.
This agreement is in response to previous threats to hike tariffs on patented pharmaceutical products, with potential rates floated up to double the cost.
"This arrangement between the United Kingdom bolsters the worldwide climate for innovative medicines and establishes much-needed balance to American-British drug exports," an announcement said.
Commercial Impact
Pharmaceuticals are one of the UK's most significant exports to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Export figures reveal that in the year to the end of the third quarter, the UK exported drugs valued at over eleven billion pounds to the US. This figure made up 17.4% of total UK exports in that timeframe.
"This deal protects employment, stimulates investment and facilitates the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The agreement entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must return to the NHS to prevent overspending will be capped at 15%. Previously, rebates topped twenty percent.
Broader Context
This agreement follows a long-running dispute between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were intensified by arguments that US consumers were charged a premium for the identical medicines than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been paused or abandoned, while substantial investments have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
